Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

November 1, 2018November 1, 2018

B. bronchiseptica Infection Causes Varied Symptoms in Non-CF Bronchiectasis Patients, Case Series Shows

News

Infection with the bacterium Bordetella bronchiseptica can have varying symptoms and be difficult to eradicate in patients with non-cystic fibrosis (CF) bronchiectasis, a case series shows. Because people, particularly those with compromised immune ... Read more

July 5, 2018July 5, 2018

Long-term Antibiotic Use May Work to Reduce Flares in Bronchiecstasis Patients, Study Says

News

At least three months of antibiotic treatment reduced the number of exacerbations experienced by people with stable non-cystic fibrosis bronchiecstasis — both new flares and the average number of flares ... Read more

April 17, 2018April 17, 2018

Insmed Research Award Created for Non-Tuberculosis Mycobacteria Lung Disease Projects

News

The American Thoracic Society Foundation has created a $50,000 research award for projects aimed at developing better prevention, diagnosis, or treatment approaches for non-tuberculous mycobacteria (NMT) lung disease. It calls it ... Read more

September 12, 2017September 12, 2017

Anxiety and Depression Common in Bronchiectasis Patients, Study Finds

News

Researchers found that patients with bronchiectasis have higher rates of anxiety and depression than healthy subjects. They did not find an association between the severity of the condition and the occurrence of anxiety ... Read more

June 6, 2017June 6, 2017

Mortality Higher in Bronchiectasis Patients Who Also Have COPD

News

A Spanish study of patients with non-cystic fibrosis bronchiectasis (BE) found the mortality rate to be higher among those who also had chronic obstructive pulmonary disease (COPD), than in patients with ... Read more

May 16, 2017May 16, 2017

Aradigm Advances Development of Linhaliq (Formerly Pulmaquin) for Non-CF Bronchiectasis

News

Aradigm discussed data from Phase 3 trials assessing the company’s inhaled form of ciprofloxacin, called Linhaliq (formerly known as Pulmaquin), with the U.S. Food and Drug Administration (FDA) to advance the drug’s development and obtain marketing ... Read more

March 28, 2017March 28, 2017

Case Report: Patients Treated for High-risk Neuroblastoma May Develop Bronchiectasis

News

Patients who received treatment for high-risk neuroblastoma (a cancer affecting certain types of nerve tissue) and subsequently complain of a persistent cough should be examined further to rule out bronchiectasis, according to the authors of ... Read more